Galderma R&D

Other

Pipeline Programs↗

Distinct drugs in development (Preclinical–Phase 3)

Indications↗

Distinct diseases across all programs

167

Clinical Trials↗

All sponsored trials (all statuses)

Orange Book Patents

Across 2 drugs with upcoming expirations

Pipeline

Pipeline Snapshot

By Phase

1 drugs in development

Approved2

Phase 31

Phase 21

Preclinical1

By Therapeutic Area

top 3

Immunology

240%

Nephrology

120%

Dermatology

120%

R&D Momentum

45/100

Pipeline Velocity

25/100

Trial Completion Rate

97/100

Pipeline Concentration

28/100

Pipeline Freshness

81/100

Strategic Signals

↗Active in Immunology but thin pipeline — potential licensing opportunity

Activity

Key Events

Jun 26, 2026TrialA Multicenter, Open-Label, Single-Group Clinical Trial to Assess the Pharmacokinetics, Safety and Efficacy of Nemolizumab (CD14152) in Pediatric Subjects (Aged 2 to 11 Years) With Moderate-to-Severe Atopic Dermatitis

Jun 24, 2026TrialA Multicenter, Open-Label, Single-Group Clinical Study to Assess the Pharmacokinetics, Safety and Efficacy of Nemolizumab in Pediatric Subjects (Aged 6 to 23 Months) With Moderate-to-Severe Atopic Dermatitis Not Adequately Controlled With Topical Therapy

Dec 15, 2025TrialA Study of Nemolizumab for the Treatment of Adults With Systemic Sclerosis

Oct 20, 2025TrialProof of Concept Study to Assess the Pharmacokinetics/Pharmacodynamics of Nemolizumab in Adults With Chronic Pruritus of Unknown Origin (CPUO)

Sep 23, 2025TrialA Study to Compare the Efficacy, Safety and Pharmacokinetics of Trifarotene 50 mcg/g Cream in Chinese Subjects With Acne Vulgaris

Aug 12, 2025TrialA Clinical Study to Assess Efficacy and Tolerability of a Topical Skincare Product on Adults With Mature, Crepey Skin

Apr 8, 2024TrialA Study to Assess Efficacy and Tolerability of Topical Skincare Products on Psoriasis Patients

Aug 25, 2023TrialA Clinical Study to Assess the Efficacy and Safety of a Healing Ointment on Diaper Rash

3 more events

Jan 23, 2023TrialAssess Aesthetic Improvement With QM1114-DP in Subjects With Moderate to Severe Lateral Canthal Lines and Glabellar Lines

Jan 1, 2023TrialEfficacy and Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis With Inadequate Response to or for Whom Cyclosporine A is Not Medically Advisable

Aug 17, 2022TrialHealing Ointment Usage Post-surgical Procedure

Details

Company Info

Company Overview

—

Mkt Cap

—

Revenue

—

Cash

Patent Expirations

4 patent groups across drugs · Source: FDA Orange Book

DrugExpires

Differin2 patentsSep 15, 2026 DifferinMay 31, 2028 AkliefJul 19, 2031 Aklief2 patentsMay 30, 2033

Pipeline

Drug Pipeline

Indication

Preclinical

Phase 1

Phase 2

Phase 3

Approved

RezzayoPreclinical

Chronic Spontaneous Urticaria

RezzayoPhase 2

Eczematoid Dermatitis

RezzayoPreclinical

Prurigo Nodularis

RezzayoPreclinical

Pruritus

RezzayoPreclinical

Immunology

Atopic Dermatitis

RezzayoPhase 3

Moderate to Severe Atopic Dermatitis

RezzayoPhase 2

Psoriasis

CetaphilApproved

Systemic Scleroderma

RezzayoPhase 2

Systemic Sclerosis

RezzayoPhase 2

Nephrology

Chronic Kidney Disease

RezzayoPhase 2

Unknown / Other

Lichen Planopilaris

RezzayoApproved

Prurigo

RezzayoPreclinical

Skin Disease

RezzayoPreclinical

Regulatory

Regulatory Timeline

19961 event

FDAMay 31

Differin — DIFFERIN

Application NDA020338 (NDA)

20001 event

FDAMay 26

Differin — DIFFERIN

Application NDA020748 (NDA)

20041 event

FDAJul 27

Metvixia — METVIXIA

Application NDA021415 (NDA)

20071 event

FDAJun 19

Differin — DIFFERIN

Application NDA021753 (NDA)

20101 event

FDAMar 17

Differin — DIFFERIN

Application NDA022502 (NDA)

20161 event

FDAJul 8

Differin — DIFFERIN

Application NDA020380 (NDA)

20191 event

FDAOct 4

Aklief — AKLIEF

Application NDA211527 (NDA)

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)